Physician profile
William M Oconnor
NPI 1730132507
$4,125.40
in general payments reported to CMS, 2019-2025
25 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $197 · 2021: $341 · 2022: $848 · 2023: $578 · 2024: $605 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.68 |
| Education | $171.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $881.29 | 2019-2025 | Austedo Xr, Austedo |
| Abbvie INC. | $676.41 | 2021-2025 | |
| Pfizer INC. | $566.60 | 2023-2025 | |
| Biogen, INC. | $421.70 | 2019-2025 | Vumerity, Tysabri |
| Sk Life Science, INC. | $352.52 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $333.11 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $194.56 | 2019-2020 | |
| Harmony Biosciences LLC | $144.88 | 2022-2024 | Wakix |
| E.R. Squibb & Sons, L.L.C. | $107.10 | 2022 | |
| Celgene Corporation | $64.08 | 2021 | |
| Ucb, INC. | $54.02 | 2025 | Rystiggo, Zilbrysq |
| Lilly USA, LLC | $45.62 | 2023-2025 | Emgality, Kisunla, Reyvow |
| Eisai INC. | $45.11 | 2025 | |
| Sumitomo Pharma America, INC. | $29.02 | 2023 | Aptiom |
| Sunovion Pharmaceuticals INC. | $25.29 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $24.68 | 2025 | Onpattro |
| Alexion Pharmaceuticals, INC. | $24.63 | 2025 | Ultomiris |
| Upsher-Smith Laboratories LLC | $24.59 | 2021 | |
| Lundbeck LLC | $23.98 | 2025 | Rexulti |
| Genentech USA, INC. | $21.89 | 2025 | Ocrevus Zunovo |
| Currax Pharmaceuticals LLC | $14.09 | 2022 | |
| Allergan, INC. | $13.73 | 2020 | |
| Emd Serono, INC. | $12.94 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.90 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.